Edwards Lifesciences (NYSE:EW) Updates FY24 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share guidance of $2.70-2.80 for the period, compared to the consensus earnings per share estimate of $2.75. The company issued revenue guidance of high end of $6.3-3.6 billion, compared to the consensus revenue estimate of $6.52 billion. Edwards Lifesciences also updated its FY 2024 guidance to 2.700-2.800 EPS.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded down $1.58 during trading on Friday, reaching $86.43. The company’s stock had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The stock has a 50-day moving average price of $90.28 and a two-hundred day moving average price of $78.89. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. Edwards Lifesciences has a one year low of $60.57 and a one year high of $96.12. The stock has a market capitalization of $52.02 billion, a P/E ratio of 37.25, a price-to-earnings-growth ratio of 4.29 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.34% and a net margin of 23.01%. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. As a group, sell-side analysts anticipate that Edwards Lifesciences will post 2.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Morgan Stanley lifted their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an overweight rating in a research report on Thursday, March 21st. Bank of America upgraded Edwards Lifesciences from a neutral rating to a buy rating in a research report on Thursday, March 7th. OTR Global upgraded Edwards Lifesciences from a mixed rating to a positive rating in a research report on Tuesday, March 26th. Citigroup lifted their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a neutral rating in a research report on Wednesday, April 3rd. Finally, Oppenheimer lifted their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an outperform rating in a research report on Monday, March 18th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $93.33.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $94.89, for a total value of $688,426.95. Following the completion of the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at approximately $1,809,931.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $94.89, for a total value of $688,426.95. Following the completion of the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at approximately $1,809,931.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the transaction, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.